ECVT & ECCT

11/04/2026

ECCT merubah lanskap terapi kanker paru-paru stadium lanjut, meningkatkan harapan hidup secara berlipat dibanding dengan terapi tanpa ECCT. Hal ini berdasarkan hasil studi Dr. Shinichiro Akiyama dari Jeoang yang dipresentasikan dalam konferensi dunia GLOBEHEAL 2026 ke-9 yang diadakan pada tanggal 12-13 Februari 2026 di Bali.

Dr. Akiyama, profesor tamu bidang onkologi klinis pada McGill University Medical School, Canada melakukan penelitian klinis bersama tim C-Tech Labs Edwar Technology di Tangerang terkait penanganan kanker paru-paru dengan ECCT sebagai terapi utama maupun tambahan untuk kasus kanker paru-paru stadium 3 dan 4.

ECCT meningkatkan harapan hidup penderita kanker paru-paru stadium lanjut 600-800% berdampingan dengan terapi standar dibanding apabila hanya menggunakan terapi standar saja. Hal ini berdasarkan hasil studi yang dipresentasikan dalam konferensi dunia GLOBEHEAL 2026 ke-9 yang diadakan pada tanggal 12...

02/03/2026

Group B breast cancers typically react well to ECCT treatment, causing tumors up to 3-5 cm in size to go away completely and revert to normal tissue. The way that various tumor types react to electric field treatment with ECCT depends on how those cancers are classified based on their electrical index. Tools for measuring the electrical activity index, which characterizes the subtypes, are provided by ECVT.

Different varieties of breast tumors react differently to the treatment. such as shrinkage (Groups C1 and C2), solid-turn-to-cystic (Group A), and solid-turn-to-necrotic (Group D). Together with a team from CTech Labs of Indonesia, Akiyama from the Clinical Oncology Department at McGill University in Canada published the study in the Journal of the World Academy of Anti-Aging and Regenerative Medicine 2024; 6: 20–33.

Link:https://waarm.or.jp/wp-content/uploads/2025/02/20-33_ECCT-Physical-Therapy-for-Cancer_Shinichiro-Akiyama.pdf

16/01/2026

CASE: Male, 44 years old, diagnosed with diffuse neuroendocrine carcinoma at the right neck, post-chemotherapy, followed with ECCT+chemotherapy.

After completing the first six cycles of chemotherapy, the cancer continued to grow. A CT scan revealed a mass measuring nearly 10 cm, pressing on a large blood vessel in her right neck, which had already been infiltrated.

The biopsy results indicated a diffuse neuroendocrine/non-Hodgkin's lymphoma, which had infiltrated the striated muscle tissue, the main muscles responsible for head and neck movement and swallowing and speaking.

Killing cancer cells with ECCT is relatively straightforward; cells die relatively quickly, especially for high-grade cancers. However, excessive cell death in the body can overload the body due to a flood of cytokines, the body's immune response to combat the dead cells. The patient was suggested to use ECCT combined with follow-up chemotherapy.

After using the device for two months, followed by one time of second chemotherapy cycles, while still using the device, the lump shrank significantly. He completed all six chemotherapy cycles while continuing to use the device. A PET CT scan after six months showed the lump in her neck had shrunk from 10 cm to 2-3 cm.

After completing six cycles, she continued using ECCT alone to completely remove the remaining lump. After two years of use, the lump was no longer palpable. He has continued using the ECCT device for general health maintenance for five years now. His condition is relatively normal and active.

08/01/2026

Ikuti pemaparan terkait sejarah awal pengembangan teknologi ECVT yang pertama dipakai oleh NASA dan Departemen Energi Amerika Serikat hingga pengembangan terbaru teknologi turunannya yaitu alat terapi kanker ECCT di podcast Bicara Iptek oleh inventornya langsung Dr. Warsito Purwo Taruno.

Link di komen.

Membahas mengenai teknologi tomografi dengan pengembangannya dalam terapi kanker di Indonesia.Kontak tim Dr. Warsito untuk terapi Kanker bisa melalui:https:/...

03/01/2026

Lung cancer remains a leading cause of cancer-related mortality worldwide. Electro-Capacitive Cancer Therapy (ECCT), a non-invasive treatment utilizing alternating electric fields, has emerged as a promising adjunctive modality by selectively disrupting cancer cell mitosis. This study presents a case series evaluating the clinical outcomes of ECCT as an additive therapy for patients with advanced lung adenocarcinoma.

Results shows that five patients observed in this study achieved a partial response (PR), and one maintained stable disease (SD), with significant tumor regression observed across all cases. The treatment was exceptionally well-tolerated, with no severe adverse events reported. Clinical improvements were observed irrespective of the patients' EGFR mutation status.

This case series suggests that ECCT is a safe and effective adjunctive therapy for stage IV lung adenocarcinoma, significantly enhancing the efficacy of standard treatments across different molecular subtypes. These promising real-world results align with emerging evidence from larger trials and preclinical studies on electric field-based therapies. These findings warrant further investigation in larger, prospective clinical trials to establish ECCT's definitive role in precision oncology frameworks.

DOI URL:
https://dx.doi.org/10.47746/FMCR.2025.6505

基本的に正常細胞に作用しないため、副作用は抗がん剤に比べて非常に少なく、重篤な副作用は報告されていません。

03/01/2026

CASE: A 40-year-old woman was diagnosed with a bone tumor in her right thigh. It recurred two months after surgery and radiation.

A PET-CT scan two months after surgery showed recurrence in the post-surgery and radiation area, along with metastasis to the lungs and lymph nodes surrounding the trachea, bronchi, and supraclavicular and neck lymphnodes. A biopsy revealed a poorly differentiated adenocarcinoma with ALK-positive mutation detected. The mass in her right thigh likely originated from her lung.

This case is considered end-stage. Poorly differentiated adenocarcinoma is a highly aggressive type that generally has a poorer prognosis than moderately or well-differentiated types. In general, the prognosis for end-stage lung cancer is relatively poor, with survival rate only around 6-12 months even with treatment.

However, this type has a better response to ECCT than less aggressive types. Poorly differentiated adenocarcinomas have higher electrical polarity than moderately or well-differentiated types, resulting in a better response to ECCT. Cells die more quickly with exposure of the electric field, dead cells are discharged more easily due to their softer nature. Probability to achieve remission is higher regardless of staging. Metastasis is relatively less issue with ECCT as long as the spread remains in the form of small nodules, so the level of damage to the invaded tissue is not too severe.

In this case, the patient also received targeted drugs in combination with the usage of ECCT device. ECCT effectively kills malignant cells, while the targeted drugs suppress the growth factor of the cells. If both work well, remission is highly possible, even in cases with extensive spread.

The success rate of this combination therapy is still influenced by how quickly the dead cells are discharged to outside of the body through the body's natural mechanisms as well as the extent of tissue/organ damage that has been invaded by malignant cells. For cases with widespread metastasis in the form of small nodules, this is generally the case.

A CT scan after 3 months of use of the device showed the main mass in the lung had shrunk from 3.8x2.3 cm to 1.8x1.3 cm. Another PET-CT scan after 6 months of usage of the device showed the malignant mass had been relatively cleared. The patient's general condition is relatively normal.

23/07/2025

The latest advancement in ECCT shows that well-differentiated adenocarcinoma with a wild-type EGFR mutation dies and changes into a mass with high cholesterol content within 30 minutes of being subjected to an electric field. It is also possible for a 5-cm-diameter lump of recurrent tumor to shrink to normal tissue in two months.

07/07/2025

In 6 months, ECCT removes the primary tumor of high-grade adenocarcinoma of the prostate, as well as all metastatic lymph nodes and bone lesions, with the exception of the area of the face and neck that is uncovered by the device, as seen in this case.

CASE: A 72-year-old French man was diagnosed with prostate cancer with a Gleason score of 9/10 in September 2023. The PET scan results revealed that cancer cells had penetrated the entire prostate gland, spread to lymph nodes in the pelvis and surrounding the aortic blood veins, and reached locations in the hip bones. It was revealed that his disease was already at stage 4.

He then decided to take hormone-suppressing medication while receiving ECT (Electric Cancer Therapy) in Germany and taking the GcMaf immunotherapy supplement from Japan. After about a year of medication, a PET scan revealed that the spread to the lymph nodes had spread to the entire chest and neck area, and the bone spread had reached places up to the skull; meanwhile, the mass in the prostate had completely filled the prostate.

He first used the ECCT device in December 2024. He had no severe concerns while using the ECCT devices. Because the cancer spreads in the form of small points, despite its widespread nature, and the cell type is vulnerable (easily destroyed by an electric field) and the dead cells are relatively easy to leave from the body by excretion such as sweating, urine, and f***s. Even if the cancer has spread far, it can still be completely treated as long as the extended area is well covered by the device.

The PET scan outcomes after 6 months of implementing ECCT revealed that the cancer mass was mostly clean in the prostate and all areas where it spread, including lymph nodes from the pelvis to the chest and all bones, with the exception of the face and neck, which he refused to cover from the start. After reviewing the PET scan results, he agreed to use the new device, which covers his full body, including the face and the neck area. His overall condition is quite normal.

21/06/2025

Case: ECCT for Lung Adenocarcinoma with Positive EGFR Mutation.

A 30-year-old woman was diagnosed with lung cancer in October 2024. She initially complained of heavy, short-breathing and significant chest pain.A core biopsy and EGFR gene mutation screening revealed an adenocarcinoma type with a positive mutation. Her doctor prescribed gefitinib, a targeted therapy tablet, and she began using ECCT practically simultaneously.

The biopsy result indicates no tissue differentiation. The response of ECCT to adenocarcinoma cancer cell types is determined by the cells' electrical polarity, which correlates with their malignancy grade. For high-grade (high electrical polarity, e.g., undifferentiated adenocarcinoma), 70-80% of the tumor mass (independent of size) can be reduced in 1-3 months. The intermediate grade shrinks by 40-50% within 3-6 months. Low-grade (well-differentiated adenocarcinoma) requires 6-12 months to achieve a 20-30% decrease. Combining with targeted drug administration often improves the efficacy of the therapy while minimizing inflammation, especially when the mass volume is substantial.

Her response to the combination therapy was relatively positive and speedy. Her complaints of shortness of breath and soreness subsided within a month. The progress of ECCT treatment is generally determined by the smoothness of the excretion process. In her case, the majority of the elimination was through thick phlegm. Along with the smooth release of excessive and thick phlegm, her condition has improved, and her complaints have steadily lessened. The CT scan results after three months of use revealed a mass reduction of approximately 30-40% by volume. The response is consistent with a medium- to high-grade adenocarcinoma.

After 6 months of using the device, her symptoms have mostly vanished. She resumed her everyday routines as usual. The CT scan results suggest that the tumor mass has shrunk further, down to 50% of its original size. Her lungs retain some fluid, but her overall health and condition are just fine.

02/06/2025

CASE: High-grade adenocarcinoma with EGFR-positive mutation treated with ECCT and targeted drug.

The 76-year-old Mr. Hasni was initially diagnosed with lung cancer in his right lung, which was 2X6X3 cm. The biopsy revealed an EGFR mutation-positive adenocarcinoma type. The doctor had originally intended to operate but canceled it after discovering metastases in both the left and right lungs. The sole medication that was administered to him was Tagrisso.

After two months of targeted drug prescription, a CT scan examination revealed that the cancer had continued to grow quickly, reaching 4X7X4 cm, three times its original volume, and that the dissemination in both lung fields had become more widespread. Additionally, Mr. Hasni's health is deteriorating. He then combined the specific oral medication with ECCT. Highly malignant cancer cells are killed by the ECCT device in a short period of time (one to three months), and the targeted chemotherapy medication successfully inhibits the endocytosis response, facilitating a seamless and efficient procedure and averting a cytokine storm that would otherwise cause extensive inflammation.

Following three months of ECCT cancer treatment, Mr. Hasni's tumor shrank to 1X2X1.5 cm, a 97% reduction in size; the spread also became much less pronounced. Six months of continuous use of the device further decreased the cancer mass to the calcium residue that remained. He is currently in normal condition and in excellent health at the age of 77.

08/05/2025

CASE: ECCT combined with radiation therapy for stage 4 lung adenocarcinoma

Low-grade, well-differentiated adenocarcinoma with EGFR wild-type mutation responds slowly to ECCT. However, when combined with radiation therapy, it results in dramatic shrinking of this stage-4 lung cancer that has already infiltrated the muscle by 80-90% of its volume in 6 months. ECCT was utilized both before and after radiation therapy to provide long-term protection and prevent recurrence and metastasis. CT scan after 9 months with continued usage of ECCT showed further reduction in the tumor mass. The clinical condition of the patient is relatively normal.

25/04/2025

CASE: Low grade lung adenocarcinoma with ECCT combined with Chemotherapy

Low-grade adenocarcinoma often responses slowly to ECCT treatment. However, combining ECCT with chemotherapy after 2-3 months of use reveals a considerable reduction of 70-80% by volume in 6 months in a case of a 52-year-old male diagnosed with well-differentiated (low grade) adenocarcinoma with EGFR-negative mutation.